VBI Vaccines provides a recombinant virus‑like particle (VLP) platform that displays antigens on self‑assembling nanoparticles to elicit strong humoral and cellular immunity. The modular system enables rapid development of prophylactic vaccines and therapeutic cancer immunotherapies for pharmaceutical partners, with scalable GMP manufacturing and integrated adjuvant formulations.
Funding
$2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients lack broadly protective vaccines for emerging infectious diseases and effective immunotherapies for aggressive cancers, leading to high morbidity, mortality, and limited treatment options. Traditional vaccine platforms often require complex manufacturing and may not elicit strong cellular immunity needed for tumor control.
Solution
VBI Vaccines employs a virus‑like particle (VLP) platform that structurally mimics native viruses to present antigens in their native conformation, thereby inducing robust humoral and cellular immune responses. The platform is applied to both prophylactic vaccines—aimed at preventing infection—and therapeutic immunotherapeutics designed to target malignant cells. By leveraging recombinant expression systems, VBI can rapidly generate VLPs for a wide range of pathogen and tumor antigens, supporting a flexible pipeline across infectious disease and oncology indications. Clinical development follows a streamlined path from IND filing to Phase 2 trials, with data integrated into a cloud‑based analytics suite for immunogenicity monitoring. Partnerships and licensing agreements enable external developers to access the VLP technology for co‑development or white‑label products, expanding reach while sharing development risk.
Target Audience
The primary customers are pharmaceutical and biotech firms seeking a versatile VLP platform for vaccine or cancer‑immunotherapy development, as well as public‑health agencies and oncology centers that require advanced immunologic solutions for high‑burden diseases.
Features
- Recombinant VLP architecture that displays multiple copies of target antigens on a self‑assembling nanoparticle scaffold, enhancing B‑cell epitope density and T‑cell cross‑presentation.
- Modular design allowing rapid substitution of antigen sequences, supporting swift response to emerging pathogens or tumor neo‑antigens.
- Scalable, GMP‑compliant manufacturing using yeast or insect cell expression systems, reducing production lead times and cost of goods.
- Integrated adjuvant formulation library to tailor innate immune activation for either Th1‑biased anti‑tumor responses or balanced humoral immunity for prophylaxis.
- Preclinical and clinical data packages demonstrating high neutralizing antibody titers and CD8⁺ T‑cell activation across multiple disease models.
- Secure API and data‑sharing framework for partner companies to access immunogenicity readouts, pharmacokinetic profiles, and safety metrics in real time.
- Intellectual property portfolio covering VLP core scaffold, antigen insertion methods, and adjuvant‑VLP synergistic formulations.